RTC
TXMD icon

Riverview Trust Company’s TherapeuticsMD TXMD Stock Holding History

Riverview Trust Company’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4
Closed -$1K – 400
2019
Q1 		$1K Buy
+4
New +$1.06K ﹤0.01% 437

Other funds holding TXMD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverview Trust Company's TXMD Position: Q2 2019 in Review

Riverview Trust Company sold out of TherapeuticsMD (TXMD) in Q2 2019, closing a stake of 4 shares — an estimated $1K sold.

Riverview Trust Company first reported a position in TXMD in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 148 funds tracked by Wall St. Rank hold TXMD as of Q2 2019.

  • Riverview Trust Company reported no remaining TherapeuticsMD position as of Q2 2019 after selling out during the quarter.
  • Riverview Trust Company sold 4 TherapeuticsMD shares in Q2 2019, an estimated $1K.
  • Riverview Trust Company first reported a position in TherapeuticsMD in Q1 2019 and held it in 1 quarter.
  • Riverview Trust Company's TherapeuticsMD position peaked at $1K in Q1 2019.
  • 148 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2019.

Based on Riverview Trust Company's 13F filing for Q2 2019, filed 12 Jul 2019.